Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Is There Cause for Alarm with Cardano (ADA)? Renowned Analyst Issues Major Warning

Is There Cause for Alarm with Cardano (ADA)? Renowned Analyst Issues Major Warning

BitcoinSistemiBitcoinSistemi2026/10/24 12:57

In his latest technical analysis of Cardano (ADA) price, crypto analyst Ali Martinez stated that the altcoin has lost a significant support level and may be facing a deeper correction.

According to the chart shared by Martinez, Cardano has been moving within an ascending parallel channel since the end of June. During this period, the ADA price rose from $0.138 to $0.282, showcasing a remarkable performance.

However, the analyst stated that with the recent price movements, ADA has broken below the lower boundary of the ascending channel, which technically signals a decline.

According to Martinez, the most critical level to watch for Cardano’s price is $0.220. He stated that if this level continues to act as resistance, selling pressure could increase, predicting that ADA could lose approximately 20% of its value, falling to $0.166.

At the time of writing, ADA is trading at $0.208.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks